161 FDA warning letters name a GLP-1 drug, Oct 2023 to Sep 2026

Every letter, newest first

Each links to a page with FDA’s record for that letter and a verbatim excerpt, and from there to the letter itself on fda.gov.

How this list is built

• We search FDA’s warning-letter index for semaglutide, tirzepatide, liraglutide, retatrutide and GLP-1, then open every letter it returns. A letter stays on the list only if its own text names one of them.
• Recipient, dates, issuing office, subject and MARCS-CMS number are copied from FDA’s pages. The excerpt on each record page is quoted word for word.
• Anything FDA does not publish reads “Not published by FDA”. We do not fill gaps.
• Source: FDA warning letters index ↗, read Oct 3, 2026. See also FDA’s 503B outsourcing facility register.